Tasigna's Atherosclerosis Warnings is Rarely Seen by Cancer Patients

Even a black box warning can go unnoticed by patients with cancer that are fighting for their lives

Wednesday, November 28, 2018 - When a cancer patient is battling non-Hodgkin's lymphoma, the last thing on their minds is the future medical complications that the treatments may cause. Cancer patients have to deal with nausea, vomiting, weight loss, and hair loss in the present time so the possibilities of contracting heart disease someday down the road really does not phase them. Cancer can be a death sentence when it is diagnosed in its latter stages and chemotherapy patients are willing to do or try just about anything. Cancer doctors are concerned primarily with their patient's disease and doing anything they can to get their cancer into remission.

The drug that is proving to be the most effective in treating late-stage non-Hodgkin's lymphoma (NHL) is Tasigna manufactured by Novartis AG. Tasigna is so effective in causing a patient's NHL to go into and to stay in remission that the FDA has granted the company permission to claim on their label that patients may someday be able to stop taking the drug altogether, an unprecedented admission by the FDA. Prior to taking Tasigna, cancer patients were faced with a lifetime of taking their cancer medications.

Unfortunately, however, Tasigna's cancer-fighting strength comes at a devastating price. Tasigna is also proving to cause a life-threatening blood flow condition in an alarmingly high number of cancer patients taking the medication. Most cancer patients are unaware of the atherosclerosis side effects of anti-cancer chemotherapy drug Tasigna until it is too late and they are faced with having to undergo coronary bypass surgery. Tasigna atherosclerosis problems and side effects include amputation, atherosclerosis, cardiovascular problems and peripheral arterial disease.

Unlike cancer that can go into remission, atherosclerosis is permanent, irreversible, and eventually fatal. Because of this, the FDA requires Tasigna to carry a black box warning as the drug has the potential to cause serious injury or death. Unfortunately, doctors and patients never get to see the warning on the drug's packaging that includes the statement "may cause sudden death from heart attack." Other aspects of Tasigna's warning includes the fact that the drug causes a roughening of the inner walls of the major arteries leading to the heart, lungs, and brain. Once the smooth surfaces of the artery's inner walls are scared and roughened, they can never return to their original silky-smooth state and plaque will stick and build up until removed or the flow of blood is bypassed. The rapid accumulation of plaque within the artery's interior can cause decreased blood flow. When that occurs patients become noticeably more exhausted. Unfortunately, the symptoms of atherosclerosis go unnoticed because they are mistaken for the symptoms of cancer or the side-effects of chemotherapy itself. If not immediately treated with bypass surgery, atherosclerosis can lead to amputations, strokes and heart attack, not exactly the positive outcome cancer patients expect from the wonder drug.

Patients suffering from Tasigna atherosclerosis may be eligible to file a claim against the drug's maker Novartis AG, a company with a checkered history of concealing the side effects of their drugs. Novartis has been fined by government agencies in Japan, Korea, and the United States where the company settled for paying $390 million of the $1 billion dollar fine leveled against them for fraudulently representing drugs like Tasigna.

More Recent Tasigna Atherosclerosis Lawsuit News:

No-Cost, No-Obligation Tasigna Lawsuit Case Review If You or a Loved One Suffered from Tasigna Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.